Determining Change in Cardiovascular and Metabolic Risks in Patients with Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
We are looking for people newly diagnosed with chronic phase chronic myeloid leukemia (CP-CML) who have not yet started treatment with BCR-ABL1 tyrosine kinase inhibitors (TKIs). This study focuses on the cardiovascular and metabolic risks of TKIs.
This study is observational and does not require you to take any medication aside from the treatment that you are getting under the medical care of your doctor. No compensation is provided. You may not personally benefit from being in this study. However, by serving as a participant, you may help us learn how to benefit patients in the future
Chronic Myeloid Leukemia
Chronic Myelogenous Leukemia
You must be:
1. at least 18 years of age,
2. newly diagnosed chronic phase of Ph+ or CP-CML, confirmed with cytogenetic and/or molecular testing at baseline
3. going to start taking dasatinib, imatinib, or nilotinib, but have not yet started treatment
4. willing and able to come to routine office visits
18 - 100
Healthy Volunteers Needed
Duration of Participation
This research study is expected to last 24 months.
Knight Cancer Intake Center: (503)494-7999